In an unusual move, the FDA recently announced its approval of a lung cancer drug, Tagrisso, under its fast-track program. The drug treats a specific type of lung cancer categorized by a genetic mutation that causes tumors to resist traditional therapies. Lung cancer lawyers at Pintas & Mullins discuss this new drug, the patients eligible to receive it, and it’s astronomically high cost below.
Tagrisso, manufactured by AstraZeneca, will cost $12,750 for a month’s supply. Financial experts project the drug to generate more than $1 billion in sales in 2020, though AstraZeneca expects peak sales of $3 billion per year. The company claims patients with adequate insurance will not pay more than $25 per month. If a patients’ insurance does not cover Tagrisso, the company will direct the individual to an organization that supports cancer patients.